Zhaohui Su, VP of Biostatistics at Ontada, shared a post on LinkedIn:
“Adaptive designs are becoming increasingly common in clinical trials across various therapeutic areas, with adaptive randomization (RAR) emerging as a significant approach. This is particularly relevant in emergency care or severe medical conditions, where RAR allows for more individuals to receive treatments that show early signs of benefit.
The power of RAR:
- Maximizing power for the most promising treatment as evidence accumulates
- Allocating more patients to options demonstrating greater benefit
- Reducing exposure to less effective or non-beneficial treatments
- Accelerating learning when time-sensitive decisions are critical
It is encouraging to see adaptive methods actively enhancing patient care and generating meaningful evidence.”
Title: Response adaptive randomisation in clinical trials: Current practice, gaps and future directions
Authors: Isabelle Wilson, Steven Julious, Christina Yap, Susan Todd, Munyaradzi Dimairo
Read the full article here.
Other articles about Zhaohui Su on OncoDaily.